Human iPSC neurons display activity-dependent neurotransmitter secretion: Aberrant catecholamine levels in schizophrenia neurons

Stem Cell Reports

Volumn 3, Issue 4, 2014, Pages 531-538

  Hook, Vivian ^a,b,c   Brennand, Kristen J ^d,e   Kim, Yongsung ^d   Toneff, Thomas ^a   Funkelstein, Lydiane ^a   Lee, Kelly C ^a   Ziegler, Michael ^c   Gage, Fred H ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; DOPAMINE; DYNORPHIN; ENKEPHALIN; NEUROTRANSMITTER; NORADRENALIN; POTASSIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ARTICLE; CELL ACTIVITY; CELL LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NEURAL STEM CELL; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PLURIPOTENT STEM CELL; SCHIZOPHRENIA; ADULT; CASE CONTROL STUDY; CELL CULTURE; CYTOLOGY; EXOCYTOSIS; FEMALE; INDUCED PLURIPOTENT STEM CELL; MALE; METABOLISM; NERVE CELL; NEWBORN;

ADULT; CASE-CONTROL STUDIES; CATECHOLAMINES; CELLS, CULTURED; DYNORPHINS; ENKEPHALINS; EXOCYTOSIS; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFANT, NEWBORN; MALE; NEURAL STEM CELLS; NEURONS; SCHIZOPHRENIA;

EID: 84908030684     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2014.08.001     Document Type: Article

References (29)

1. M. Akil, C.L. Edgar, J.N. Pierri, S. Casali, and D.A. Lewis Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects Biol. Psychiatry 47 2000 361 370
2. M.M. Behrens, S.S. Ali, D.N. Dao, J. Lucero, G. Shekhtman, K.L. Quick, and L.L. Dugan Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase Science 318 2007 1645 1647
3. K.J. Brennand, A. Simone, J. Jou, C. Gelboin-Burkhart, N. Tran, S. Sangar, Y. Li, Y. Mu, G. Chen, and D. Yu Modelling schizophrenia using human induced pluripotent stem cells Nature 473 2011 221 225
4. K. Brennand, J.N. Savas, Y. Kim, N. Tran, A. Simone, K. Hashimoto-Torii, K.G. Beaumont, H.-J. Kim, A. Topol, and I. Ladran Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia Mol. Psychiatry 2014 2014 1 10.1038/mp.2014.22
5. A. Cavallero, A. Marte, and E. Fedele L-aspartate as an amino acid neurotransmitter: mechanisms of the depolarization-induced release from cerebrocortical synaptosomes J. Neurochem. 110 2009 924 934
6. J.T. Coyle, and G.T. Konopask The neurochemistry of schizophrenia S.T. Brady, G.J. Siegel, R. Wayne Albers, D.L. Price, Basic Neurochemistry 8th edition 2012 Elsevier Amsterdam 1000 1011
7. D. Eyles, J. Feldon, and U. Meyer Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models Transl. Psychiatr. 2 2012 e81
8. L. Funkelstein, W.D. Lu, B. Koch, C. Mosier, T. Toneff, L. Taupenot, D.T. O'Connor, T. Reinheckel, C. Peters, and V. Hook Human cathepsin V protease participates in production of enkephalin and NPY neuropeptide neurotransmitters J. Biol. Chem. 287 2012 15232 15241
9. R.W. Heinrichs, and K.K. Zakzanis Neurocognitive deficit in schizophrenia: a quantitative review of the evidence Neuropsychology 12 1998 426 445
10. R.W. Holz, and S.K. Fisher Synaptic transmission and cellular signaling: an overview S.T. Braday, G.J. Siegel, R.W. Alberts, D.L. Price, Basic Neurochemistry 2012 Academic Press Amsterdam 236 257
11. V. Hook, L. Funkelstein, D. Lu, S. Bark, J. Wegrzyn, and S.R. Hwang Proteases for processing proneuropeptides into peptide neurotransmitters and hormones Annu. Rev. Pharmacol. Toxicol. 48 2008 393 423
12. E.R. Kandel, J.H. Schwartz, and T.M. Jessell Principles of Neural Science 2000 McGraw-Hill New York 251 277
13. T. Kato, Y. Abe, H. Sotoyama, A. Kakita, R. Kominami, S. Hirokawa, M. Ozaki, H. Takahashi, and H. Nawa Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia Mol. Psychiatry 16 2011 307 320
14. B. Kennedy, and M.G. Ziegler A more sensitive and specific radioenzymatic assay for catecholamines Life Sci. 47 1990 2143 2153
15. E. Kiskinis, and K. Eggan Progress toward the clinical application of patient-specific pluripotent stem cells J. Clin. Invest. 120 2010 51 59
16. H.Y. Meltzer, B.W. Massey, and M. Horiguchi Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia Curr. Pharm. Biotechnol. 13 2012 1572 1586
17. F.S. Menniti, C.W. Lindsley, P.J. Conn, J. Pandit, P. Zagouras, and R.A. Volkmann Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks Curr. Top. Med. Chem. 13 2013 26 54
18. Bda.S. Paulsen, R. de Moraes Maciel, A. Galina, M. Souza da Silveira, C. dos Santos Souza, H. Drummond, E. Nascimento Pozzatto, H. Silva Jr., L. Chicaybam, and R. Massuda Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient Cell Transplant. 21 2012 1547 1559
19. M. Peitz, J. Jungverdorben, and O. Brüstle Disease-specific iPS cell models in neuroscience Curr. Mol. Med. 13 2013 832 841
20. E. Perez-Costas, M. Melendez-Ferro, M.W. Rice, R.R. Conley, and R.C. Roberts Dopamine pathology in hydroxylase in the substantia nigra Front Psych. 3 2012 31
21. O. Robicsek, R. Karry, I. Petit, N. Salman-Kesner, F.J. Müller, E. Klein, D. Aberdam, and D. Ben-Shachar Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients Mol. Psychiatry 18 2013 1067 1076
22. P. Seeman Dopamine receptors and the dopamine hypothesis of schizophrenia Synapse 1 1987 133 152
23. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nat. Rev. Drug Discov. 11 2012 367 383
24. M.A. Snyder, and W.J. Gao NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia Front. Cell. Neurosci. 7 2013 31
25. T. Toneff, L. Funkelstein, C. Mosier, A. Abagyan, M. Ziegler, and V. Hook Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters Peptides 46 2013 126 135
26. D.W. Volk, and D.A. Lewis Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia Neuroscience 248C 2013 154 164
27. J.E. Young, and L.S. Goldstein Alzheimer's disease in a dish: promises and challenges of human stem cell models Hum. Mol. Genet. 21 R1 2012 R82 R89
28. J.W. Young, S.B. Powell, and M.A. Geyer Mouse pharmacological models of cognitive disruption relevant to schizophrenia Neuropharmacology 62 2012 1381 1390
29. D.X. Yu, F.P. Di Giorgio, J. Yao, M.C. Marchetto, K. Brennand, R. Wright, A. Mei, L. McHenry, D. Lisuk, and J.M. Grasmick Modeling hippocampal neurogenesis using human pluripotent stem cells Stem Cell Rep. 2 2014 295 310